Pilot Study of Ponatinib in Biliary Cancer Patients With FGFR2 Fusions

Trial Profile

Pilot Study of Ponatinib in Biliary Cancer Patients With FGFR2 Fusions

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 05 Oct 2017

At a glance

  • Drugs Ponatinib (Primary)
  • Indications Biliary cancer
  • Focus Therapeutic Use
  • Most Recent Events

    • 29 Sep 2017 Status changed from suspended to active, no longer recruiting.
    • 18 Jul 2017 Status changed from recruiting to suspended.
    • 10 Jun 2017 Biomarkers information updated
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top